Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Phase 1 Recruiting
51 enrolled
CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
Phase 1 Recruiting
42 enrolled
A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas
Phase 1 Recruiting
135 enrolled
Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors
Phase 1 Recruiting
48 enrolled
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Phase 1 Recruiting
914 enrolled
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
Phase 1 Recruiting
258 enrolled
A Study of CHS-114 in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Phase 1 Recruiting
154 enrolled
IDOV-Immune for Advanced Solid Tumors
Phase 1 Recruiting
78 enrolled
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Phase 1 Recruiting
714 enrolled
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Phase 1 Recruiting
240 enrolled
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
450 enrolled
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
Phase 1 Recruiting
100 enrolled
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
Phase 1 Recruiting
405 enrolled
A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors
Phase 1 Recruiting
214 enrolled
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Phase 1 Recruiting
150 enrolled
VISTA
Phase 1 Recruiting
45 enrolled
A Study of MGC026 in Participants With Advanced Solid Tumors
Phase 1 Recruiting
250 enrolled
A Study of SH009 Injection in Patients With Advanced Solid Tumors.
Phase 1 Recruiting
150 enrolled
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Phase 1 Recruiting
243 enrolled
Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors
Phase 1 Recruiting
18 enrolled
A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
Phase 1 Recruiting
270 enrolled
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
132 enrolled
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
Phase 1 Recruiting
145 enrolled
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
Phase 1 Recruiting
158 enrolled
Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis
Phase 1 Recruiting
15 enrolled
Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy
Phase 1 Recruiting
20 enrolled
NeoTISLEGA
Phase 1 Recruiting
18 enrolled
Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients
Phase 1 Recruiting
18 enrolled
Adaptive Radiation for Abdominopelvic Metastases
Phase 1 Recruiting
30 enrolled
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or Bevacizumab
Phase 1 Recruiting
512 enrolled
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
Phase 1 Recruiting
149 enrolled
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
Phase 1 Recruiting
260 enrolled
A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors
Phase 1 Recruiting
20 enrolled
A Study of NX-1607 in Adults With Advanced Malignancies
Phase 1 Recruiting
345 enrolled
A First-in-Human Escalation and Expansion Study of Patients With Advanced Solid Tumors
Phase 1 Recruiting
94 enrolled
Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients
Phase 1 Recruiting
68 enrolled
SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
Phase 1 Recruiting
96 enrolled
A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors
Phase 1 Recruiting
21 enrolled
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Phase 1 Recruiting
30 enrolled
Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors.
Phase 1 Recruiting
98 enrolled
PIPAC-NAL-IRI
Phase 1 Recruiting
45 enrolled
HS-10502
Phase 1 Recruiting
157 enrolled
RIOT3
Phase 1 Recruiting
18 enrolled
Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors
Phase 1 Recruiting
12 enrolled
Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors
Phase 1 Recruiting
12 enrolled
Brodalumab in the Treatment of Immune-Related Adverse Events
Phase 1 Recruiting
11 enrolled
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
Phase 1 Recruiting
30 enrolled
BC001 in Combination with Sintilimab and XELOX in the Treatment of HER-2 Negative Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma.
Phase 1 Recruiting
80 enrolled
Personalized DC Vaccine for Postoperative Cancer
Phase 1 Recruiting
80 enrolled
Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours
Phase 1 Recruiting
70 enrolled